Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial

Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced that its Phase IIb/III SLS-005 (trehalose) study has been selected by Sean M. Healey & AMG Centre for ALS at Massachusetts General Hospital to be part of the HEALEY ALS platform Study. This is the first-ever study platform for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) treatment. SLS-005 […]